Name
Lymphocyte-depleted classic Hodgkin lymphoma
ICD-O-1 Morphology
9653/3: Hodgkin lymphoma, lymphocytic depletion, NOS
Effective
1978 - 1991
ICD-O-2 Morphology
9653/3: Hodgkin lymphoma, lymphocytic depletion, NOS
Effective
1992 - 2000
ICD-O-3 Morphology
9653/3: Hodgkin lymphoma, lymphocytic depletion, NOS
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C770-C779
See Module 7. Lymph nodes (C770-C779) are the usual primary sites; however, involvement in other sites is possible. If you have confirmation that the only involved site is something other than lymph nodes, then code to that primary site.
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Lymphocyte-depleted classical Hodgkin lymphoma (LDCHL) has a predilection for retroperitoneal lymph nodes, abdominal organs, and bone marrow. Compared to other subtypes of CHL, LDCHL presents at a more advanced stage (III-IV) and with B symptoms.
Prior to modern therapy the course of LDCHL was aggressive and it has remained so in some parts of Europe and developing countries.
Prior to modern therapy the course of LDCHL was aggressive and it has remained so in some parts of Europe and developing countries.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Classical Hodgkin lymphoma, lymphocyte depletion, NOS
Hodgkin lymphoma, lymphocyte depletion, NOS
LD-HL
LDCHL
Definition
Lymphocyte-depleted classic Hodgkin lymphoma (LDCHL) is a diffuse form of classic Hodgkin lymphoma (CHL) rich in Hodgkin/Reed-Sternberg (HRS) cells and/or depleted of non-neoplastic lymphocytes. Histiocytes are usually abundant.
Definitive Diagnostic Methods
Histologic confirmation
Immunophenotyping
Genetics Data
None
Immunophenotyping
CD30+ (expression/positive)
CD79a- (no expression/negative)
EBV/LMP1+ (expression/positive)
OCT2+ (expression/positive)
PAX5+ (expression/positive)
Treatments
Chemotherapy
Hormone therapy
Radiation therapy
Transformations to
Transformations from
Same Primaries
Corresponding ICD-9 Codes
201.7 Hodgkin's disease, lymphocytic depletion
Corresponding ICD-10 Codes
C81.3 Hodgkin lymphocytic depletion
Corresponding ICD-10-CM Codes (U.S. only)
C81.3 Lymphocyte depleted Hodgkin lymphoma (effective October 01, 2015)
Signs and Symptoms
Drenching night sweats
Fatigue
Fever (for no known reason)
Painless swelling in the lymph nodes
Retroperitoneal lymphadenopathy
Skin rash or itchy skin
Weight loss (for no known reason)
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Age: 30-37 years median age
Incidence: <1% of classical Hodgkin lymphomas
Sex: male predominance
Survival: good prognosis
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Hodgkin lymphomas
Pages: 441-442
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Hodgkin lymphomas
Pages: 441-442
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Adult Hodgkin Lymphoma (HL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq
Section: General Information About Adult Hodgkin Lymphoma (HL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq